# Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

> **NCT02114658** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 18 (actual)

## Conditions studied

- Thyroid Carcinoma

## Interventions

- **DRUG:** Sorafenib (Nexavar,BAY43-9006)

## Key facts

- **NCT ID:** NCT02114658
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-15
- **Primary completion:** 2015-02-23
- **Final completion:** 2016-08-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02114658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02114658, "Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02114658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*